STOCKS TELEGRAPH

Tag: PLX stock

  • Protalix Bio Therapeutics Inc. (PLX) Rebounds Following Insider Transaction

    On Wednesday, an SEC filing was revealed regarding the insider transaction of Protalix Bio Therapeutics Inc. (PLX) stock. The company’s CEO acquired some shares of its stock on April 11, according to the filing.

    Source: Business Insider

    PLX stock while lost 1.47% in the regular session on April 13, rebounded in the after-hours thanks to the insider transaction. Investors’ interest in the stock after the transaction filing caused it to rally by 11.19% in the after-hours. Thus, the stock was trading at a price of $1.49 per share in the late trading session on Wednesday.

    PLX’s Insider Transaction

    According to the filing registered on April 13, Dror Bashan acquired 68,000 shares of the company’s stock on April 11. Mr. Bashan, the company’s President, CEO, and Director bought the stock at $1.50 a share. Hence, the total value of the transaction was $102,000.

    Following the transaction, Mr. Bashan owns the new shares directly while he is the indirect beneficial owner of 1,085,458 common stock shares.

    Market Overview

    The recombinant protein market has recently garnered much interest due to the Covid-19 pandemic. Covid-19, which has marked itself as a serious burden on the global healthcare economy, has sparked an uptick in recombinant protein-based R&D in order to develop vaccines and therapies for the disease caused by it. Another reason for increased progress in the market is the higher prevalence of chronic diseases throughout the world. Thus, inclination toward biologics/biosimilars, increased expenditure and chronic diseases are driving the recombinant protein-based therapeutics market upwards.

    Valued at $125.8 billion in 2020, the recombinant protein market is expected to grow at a CAGR of 11.2% between 2021 and 2026.

    PLX Analysis and Developments

    In 2021, the company while combating the impact of Covid-19 continued its progress towards its clinical and regulatory goals. After a successful Type A meeting with the FDA in 2021, the company is now on track for BLA resubmission of PRX-102 for Fabry disease. Moreover, the company recently shared positive results from another Fabry disease trial as well. In addition, PLX also submitted MAA in Europe and is awaiting feedback. Thus, 2022 so far has been a very fruitful year for the company as its progresses forwards in its pipeline. PLX has so far garnered gains of over 60% year to date while 2021 saw a decline of 77%.

    Conclusion

    PLX stock rebounded in late trading on Wednesday after an SEC filing revealed the insider transaction of its CEO. Investors were glad to see the company’s CEO’s confidence in it.

  • Protalix Bio Therapeutics Inc. (PLX) Down After Surging on Fabry Disease Trial Topline Data

    Protalix Bio Therapeutics Inc. (PLX) Down After Surging on Fabry Disease Trial Topline Data

    In the regular trading session on April 4, 2022, Protalix Bio Therapeutics Inc. (PLX) stock saw an upsurge of 41.90%. Trending at a hefty volume of 191.29 million shares, the stock rallied to reach $1.49 per share at the close. But inevitably this surge was followed by a downfall in the after-hours trading as stock corrections applied their pressure. Succumbing to corrections, the stock then lost 4.70% in the after-hours at $1.42 per share.

    Why PLX Surged on Monday?

    Source: MarckLogic

    The latest surge in PLX is the result of encouraging topline data from another Fabry disease trial that the company along with Chiesi Global Rare Disease shared. Chiesi Global is a unit of Chiesi Farmaceutici S.p.A.

    The company has been conducting a BALANCE Phase 3 trial of the novel therapy PRX-102 (pegunigalsidase alfa) in comparison to Farbrazyme® in Fabry disease. A multisystem disease that affects the skin, kidneys, heart, brain, and nervous system, Fabry disease can prove to be fatal.

    The topline data demonstrated that PRX-102 not only met its primary endpoint of the study but also proved general tolerability. Thus, PRX-102 proved to help decline the progression of Fabry disease. Combined with the earlier trials results, PRX-201 has proven its potential in the treatment of the disease and thus can hopefully be the new replacement therapy. Therefore, the company is now planning for regulatory submissions along with its commercialization partner Chiesi.

    How Does the Industry Look?

    Topping $1.2 trillion in sales each year, the global pharmaceutical industry is focused on improving the lives of people. Trailing the past twelve months’ data, pharmaceutical stocks have outperformed the overall market by a slight margin.

    Currently, as of Monday, the healthcare stocks have mostly been on a bullish roll with WVE, NLTX, and CGTX all making some moves but PLX topped with over 70% gains midday. So far the industry and its stocks have a bright future ahead as the need for cures and treatments will prevail as long as humans live.

    Where Does PLX Stand?

    While the company did not report much growth in its 2021 earnings, it is progressing smoothly with its pipeline. Initially failing on the BLA of its PRX-102, the latest positive data combined with the previous is now on track for BLA resubmission in H2 2022.

    Conclusion

    The company’s latest positive topline data from another Fabry disease trial had PLX rolling high on Monday. But the upsurge as expected culminated in corrections taking charge in the after hours.